
    
      A phase IIa, single-blind, placebo-controlled, crossover, multi-center, randomized study to
      assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of
      ischemia-tolerant allogeneic mesenchymal bone marrow cells to subjects with heart failure of
      non-ischemic etiology.
    
  